BioVendor
Research
and Diagnostic Products



Human sCD134 (OX40) ELISA

Product Data Sheet

Cat. No.: RAF086R

For Research Use Only

CONTENTS

» **This kit is manufactured by:**
BioVendor – Laboratorní medicína a.s.

» **Use only the current version of Product Data Sheet enclosed with the kit!**

1. INTENDED USE

The human sCD134/OX40 ELISA is an enzyme-linked immunosorbent assay for the quantitative detection of human sCD134/OX40. **The human sCD134/OX40 ELISA is for research use only. Not for diagnostic or therapeutic procedures.**

2. SUMMARY

OX40 (CD134) is a member of the tumor necrosis (TNF) receptor superfamily and known to be an important costimulatory molecule expressed on activated T-cells. Interaction of OX40 with its ligand, OX40L, is thought to be important in T cell activation through T cell/antigen-presenting cell (APC) interaction. Ligation of OX40 induces clonal expansion and survival of CD4 cells during primary responses, and results in the accumulation of greater numbers of memory cells with time.
Further OX40 has been shown to be involved in the T cell adhesion to endothelium. Induction of CD134 by Interleukin-4 has been suggested, which thus acts in a TH-2 type cytokine environment. OX40 expression is found besides T cells in a small subpopulation of macrophages, in Langerhans cells, and in B-cells in non Hodgkin's lymphoma. OX40 promotes Bcl-xL and Bcl-2 expression thus being a critical regulator of antigen-driven T cell survival. OX40 signaling renders adult T cell leukemia cells resistant to Fas-induced apoptosis.
It has been described as a molecule involved in regulating immunological tolerance, which represents a major obstacle in developing effective immunotherapy against tumors.
A soluble isoform of OX40 has been described. Measurement of this molecule may have diagnostic value in polymyositis and granulomatous myopathy, in T cell lymphoma and lymphomatoid papulosis, in proliferative lupus nephritis, in rheumatoid arthritis, in HIV infection, in viral infections of the lung, in the regulation of graft-versus-host disease, in myocarditis and dilated cardiomyopathy. The crucial role of OX40 in development of autoimmune diseases has further been shown.

3. PRINCIPLES OF THE TEST

An anti-human sCD134/OX40 coating antibody is adsorbed onto microwells.

Figure 1



Human sCD134/OX40 present in the sample or standard binds to antibodies adsorbed to the microwells. A biotin-conjugated anti-human sCD134/OX40 antibody is added and binds to human sCD134/OX40 captured by the first antibody.

Figure 2



Following incubation unbound biotin-conjugated anti-human sCD134/OX40 antibody is removed during a wash step. Streptavidin-HRP is added and binds to the biotin-conjugated anti-human sCD134/OX40 antibody.

Figure 3



Following incubation unbound Streptavidin-HRP is removed during a wash step, and substrate solution reactive with HRP is added to the wells.

Figure 4



A coloured product is formed in proportion to the amount of human sCD134/OX40 present in the sample or standard. The reaction is terminated by addition of acid and absorbance is measured at 450 nm. A standard curve is prepared from 7 human sCD134/OX40 standard dilutions and human sCD134/OX40 sample concentration determined.

Figure 5



4. REAGENTS PROVIDED

1 aluminium pouch with a **Antibody Coated Microtiter Strips** with monoclonal antibody to human sCD134/OX40
1 vial (100 µl) **Biotin-Conjugate** anti-human sCD134/OX40 monoclonal antibody
1 vial (150 µl) **Streptavidin-HRP**
2 vials human sCD134/OX40 **Standard** lyophilized, 10 ng/ml upon reconstitution
1 vial (12 ml) **Sample Diluent**
1 vial (5 ml) **Assay Buffer Concentrate** 20x (PBS with 1% Tween 20 and 10% BSA)
1 bottle (50 ml) **Wash Buffer Concentrate** 20x (PBS with 1% Tween 20)
1 vial (15 ml) **Substrate Solution** (tetramethyl-benzidine)
1 vial (15 ml) **Stop Solution** (1M Phosphoric acid)
4 **Adhesive Films**

5. STORAGE INSTRUCTIONS – ELISA KIT

Store kit reagents between 2° and 8°C. Immediately after use remaining reagents should be returned to cold storage (2° to 8°C). Expiry of the kit and reagents is stated on labels.
Expiry of the kit components can only be guaranteed if the components are stored properly, and if, in case of repeated use of one component, this reagent is not contaminated by the first handling.

6. SPECIMEN COLLECTION AND STORAGE INSTRUCTIONS

Cell culture supernatant and serum were tested with this assay. Other biological samples might be suitable for use in the assay. Remove serum from the clot as soon as possible after clotting. Pay attention to a possible **"Hook Effect"** due to high sample concentrations (see chapter 11). Samples containing a visible precipitate must be clarified prior to use in the assay. Do not use grossly hemolyzed or lipemic specimens.
Samples should be aliquoted and must be stored frozen at -20°C to avoid loss of bioactive human sCD134/OX40. If samples are to be run within 24 hours, they may be stored at 2° to 8°C (for sample stability refer to 0).
Avoid repeated freeze-thaw cycles. Prior to assay, the frozen sample should be brought to room temperature slowly and mixed gently.

7. MATERIALS REQUIRED BUT NOT PROVIDED

- 5 ml and 10 ml graduated pipettes
- 5 µl to 1000 µl adjustable single channel micropipettes with disposable tips
- 50 µl to 300 µl adjustable multichannel micropipette with disposable tips
- Multichannel micropipette reservoir
- Beakers, flasks, cylinders necessary for preparation of reagents
- Device for delivery of wash solution (multichannel wash bottle or automatic wash system)
- Microwell strip reader capable of reading at 450 nm (620 nm as optional reference wave length)
- Glass-distilled or deionized water
- Statistical calculator with program to perform regression analysis

8. PRECAUTIONS FOR USE

- All reagents should be considered as potentially hazardous. We therefore recommend that this product is handled only by those persons who have been trained in laboratory techniques and that it is used in accordance with the principles of good laboratory practice. Wear suitable protective clothing such as laboratory overalls, safety glasses and gloves. Care should be taken to avoid contact with skin or eyes. In the case of contact with skin or eyes wash immediately with water. See material safety data sheet(s) and/or safety statement(s) for specific advice.
- Reagents are intended for research use only and are not for use in diagnostic or therapeutic procedures.
- Do not mix or substitute reagents with those from other lots or other sources.
- Do not use kit reagents beyond expiration date on label.
- Do not expose kit reagents to strong light during storage or incubation.
- Do not pipette by mouth.
- Do not eat or smoke in areas where kit reagents or samples are handled.
- Avoid contact of skin or mucous membranes with kit reagents or specimens.
- Rubber or disposable latex gloves should be worn while handling kit reagents or specimens.
- Avoid contact of substrate solution with oxidizing agents and metal.
- Avoid splashing or generation of aerosols.
- In order to avoid microbial contamination or cross-contamination of reagents or specimens which may invalidate the test use disposable pipette tips and/or pipettes.
- Use clean, dedicated reagent trays for dispensing the conjugate and substrate reagent.
- Exposure to acid inactivates the conjugate.
- Glass-distilled water or deionized water must be used for reagent preparation.
- Substrate solution must be at room temperature prior to use.
- Decontaminate and dispose specimens and all potentially contaminated materials as they could contain infectious agents. The preferred method of decontamination is autoclaving for a minimum of 1 hour at 121.5°C.
- Liquid wastes not containing acid and neutralized waste may be mixed with sodium hypochlorite in volumes such that the final mixture contains 1.0% sodium hypochlorite. Allow 30 minutes for effective decontamination. Liquid waste containing acid must be neutralized prior to the addition of sodium hypochlorite.

9. PREPARATION OF REAGENTS

Buffer Concentrates should be brought to room temperature and should be diluted before starting the test procedure.
If crystals have formed in the **Buffer Concentrates**, warm them gently until they have completely dissolved.

9.1 Wash Buffer (1x)

Pour entire contents (50 ml) of the **Wash Buffer Concentrate** (20x) into a clean 1000 ml graduated cylinder. Bring to final volume of 1000 ml with glass-distilled or deionized water. Mix gently to avoid foaming. The pH of the final solution should adjust to 7.4.
Transfer to a clean wash bottle and store at 2° to 25°C. Please note that Wash Buffer (1x) is stable for 30 days.

Wash Buffer (1x) may also be prepared as needed according to the following table:

Number of Strips	Wash Buffer Concentrate (20x) (ml)	Distilled Water (ml)
1 – 6	25	475
1 – 12	50	950

9.2 Assay Buffer (1x)

Pour the entire contents (5 ml) of the **Assay Buffer Concentrate** (20x) into a clean 100 ml graduated cylinder. Bring to final volume of 100 ml with distilled water. Mix gently to avoid foaming.
Store at 2° to 8°C. Please note that the Assay Buffer (1x) is stable for 30 days.

Assay Buffer (1x) may also be prepared as needed according to the following table:

Number of Strips	Assay Buffer Concentrate (20x) (ml)	Distilled Water (ml)
1 – 6	2.5	47.5
1 – 12	5.0	95.0

9.3 Biotin-Conjugate

Please note that the Biotin-Conjugate should be used within 30 minutes after dilution.
Make a 1:100 dilution of the concentrated **Biotin-Conjugate** solution with Assay Buffer (1x) in a clean plastic tube as needed according to the following table:

Number of Strips	Biotin-Conjugate (ml)	Assay Buffer (1x) (ml)
1 – 6	0.03	2.97
1 – 12	0.06	5.94

9.4 Streptavidin-HRP

Please note that the Streptavidin-HRP should be used within 30 minutes after dilution.
Make a 1:100 dilution of the concentrated **Streptavidin-HRP** solution with Assay Buffer (1x) in a clean plastic tube as needed according to the following table:

Number of Strips	Streptavidin-HRP (ml)	Assay Buffer (1x) (ml)
1 - 6	0.06	5.94
1 - 12	0.12	11.88

9.5 Human sCD134/OX40 Standard

Reconstitute **human sCD134/OX40 standard** by addition of distilled water.
Reconstitution volume is stated on the label of the standard vial. Swirl or mix gently to insure complete and homogeneous solubilization(concentration of reconstituted standard = 10 ng/ml).
Allow the standard to reconstitute for 10-30 minutes. Mix well prior to making dilutions.
After usage remaining standard cannot be stored and has to be discarded.
Standard dilutions can be prepared directly on the microwell plate (see 10.c) or alternatively in tubes (see 0).

9.5.1 External Standard Dilution

Label 7 tubes, one for each standard point.
S1, S2, S3, S4, S5, S6, S7
Then prepare 1:2 serial dilutions for the standard curve as follows:
Pipette 225 µl of Sample Diluent into each tube.
Pipette 225 µl of reconstituted standard (concentration of standard = 10 ng/ml) into the first tube, labelled S1, and mix (concentration of standard 1 = 5 ng/ml). Pipette 225 µl of this dilution into the second tube, labelled S2, and mix thoroughly before the next transfer. Repeat serial dilutions 5 more times thus creating the points of the standard curve (see Figure 6).
Sample Diluent serves as blank.
Figure 6



10. TEST PROTOCOL

a. Determine the number of microwell strips required to test the desired number of samples plus appropriate number of wells needed for running blanks and standards. Each sample, standard, blank and optional control sample should be assayed in duplicate. Remove extra microwell strips from holder and store in foil bag with the desiccant provided at 2°-8°C sealed tightly.
b. Wash the microwell strips twice with approximately 400 µl **Wash Buffer** per well with thorough aspiration of microwell contents between washes. Allow the Wash Buffer to sit in the wells for about **10 – 15 seconds** before aspiration. Take care not to scratch the surface of the microwells.
After the last wash step, empty wells and tap microwell strips on absorbent pad or paper towel to remove excess Wash Buffer. Use the microwell strips immediately after washing. Alternatively microwell strips can be placed upside down on a wet absorbent paper for not longer than 15 minutes. **Do not allow wells to dry**.
c. **Standard dilution on the microwell plate** (Alternatively the standard dilution can be prepared in tubes - see 0):
Add 100 µl of Sample Diluent in duplicate to all **standard wells**. Pipette 100 µl of prepared **standard** (see Preparation of Standard 0, concentration = 10000 pg/ml) in duplicate into well A1 and A2 (see Table 1). Mix the contents of wells A1 and A2 by repeated aspiration and ejection (concentration of standard 1, S1 = 5000 pg/ml), and transfer 100 µl to wells B1 and B2, respectively (see Figure 7). Take care not to scratch the inner surface of the microwells. Continue this procedure 5 times, creating two rows of human sCD134/OX40 standard dilutions ranging from 5000 to 78 pg/ml. Discard 100 µl of the contents from the last microwells (G1, G2) used.

1) Figure 7



In case of an **external standard dilution** (see 0), pipette 100 µl of these standard dilutions (S1 - S7) in the standard wells according to Table 1.

Table 1
Table depicting an example of the arrangement of blanks, standards and samples in the microwell strips:

	1	2	3	4
A	Standard 1 (5000 pg/ml)	Standard 1 (5000 pg/ml)	Sample 1	Sample 1
B	Standard 2 (2500 pg/ml)	Standard 2 (2500 pg/ml)	Sample 2	Sample 2
C	Standard 3 (1250 pg/ml)	Standard 3 (1250 pg/ml)	Sample 3	Sample 3
D	Standard 4 (625 pg/ml)	Standard 4 (625 pg/ml)	Sample 4	Sample 4
E	Standard 5 (313 pg/ml)	Standard 5 (313 pg/ml)	Sample 5	Sample 5
F	Standard 6 (156 pg/ml)	Standard 6 (156 pg/ml)	Sample 6	Sample 6
G	Standard 7 (78 pg/ml)	Standard 7 (78 pg/ml)	Sample 7	Sample 7
H	Blank	Blank	Sample 8	Sample 8

d. Add 100 µl of **Sample Diluent** in duplicate to the **blank wells**.
e. Add 75 µl of **Sample Diluent** to the **sample wells**.
f. Add 25 µl of each **sample** in duplicate to the **sample wells**.
g. Prepare **Biotin-Conjugate** (see Preparation of Biotin-Conjugate 0).
h. Add 50 µl of **Biotin-Conjugate** to all wells.
i. Cover with an adhesive film and incubate at room temperature (18° to 25°C) for 2 hours, if available on a microplate shaker set at 400 rpm.
j. Prepare **Streptavidin-HRP** (refer to Preparation of Streptavidin-HRP 0).
k. Remove adhesive film and empty wells. **Wash** microwell strips 3 times according to point b. of the test protocol. Proceed immediately to the next step.
l. Add 100 µl of diluted **Streptavidin-HRP** to all wells, including the blank wells.
m. Cover with an adhesive film and incubate at room temperature (18° to 25°C) for 1 hour, if available on a microplate shaker set at 400 rpm.
n. Remove adhesive film and empty wells. **Wash** microwell strips 3 times according to point b. of the test protocol. Proceed immediately to the next step.
o. Pipette 100 µl of **TMB Substrate Solution** to all wells.
p. Incubate the microwell strips at room temperature (18° to 25°C) for about 10 min. Avoid direct exposure to intense light. **The colour development on the plate should be monitored and the substrate reaction stopped (see next point of this protocol) before positive wells are no longer properly recordable. Determination of the ideal time period for colour development has to be done individually for each assay.**

It is recommended to add the stop solution when the highest standard has developed a dark blue colour. Alternatively the colour development can be monitored by the ELISA reader at 620 nm. The substrate reaction should be stopped as soon as Standard 1 has reached an OD of 0.9 – 0.95.

q. Stop the enzyme reaction by quickly pipetting 100 µl of **Stop Solution** into each well. It is important that the Stop Solution is spread quickly and uniformly throughout the microwells to completely inactivate the enzyme. Results must be read immediately after the Stop Solution is added or within one hour if the microwell strips are stored at 2 - 8°C in the dark.
r. Read absorbance of each microwell on a spectro-photometer using 450 nm as the primary wave length (optionally 620 nm as the reference wave length; 610 nm to 650 nm is acceptable). Blank the plate reader according to the manufacturer's instructions by using the blank wells. Determine the absorbance of both the samples and the standards.

Note: In case of incubation without shaking the obtained O.D. values may be lower than indicated below. Nevertheless the results are still valid.

11. CALCULATION OF RESULTS

- Calculate the average absorbance values for each set of duplicate standards and samples. Duplicates should be within 20 per cent of the mean value.
- Create a standard curve by plotting the mean absorbance for each standard concentration on the ordinate against the human sCD134/OX40 concentration on the abscissa. Draw a best fit curve through the points of the graph (a 5-parameter curve fit is recommended).
- To determine the concentration of circulating human sCD134/OX40 for each sample, first find the mean absorbance value on the ordinate and extend a horizontal line to the standard curve. At the point of intersection, extend a vertical line to the abscissa and read the corresponding human sCD134/OX40 concentration.
- **If instructions in this protocol have been followed samples have been diluted 1:4 (25 µl sample + 75 µl Sample Diluent), the concentration read from the standard curve must be multiplied by the dilution factor (x 4).**
- **Calculation of samples with a concentration exceeding standard 1 may result in incorrect, low human sCD134/OX40 levels (Hook Effect). Such samples require further external predilution according to expected human sCD134/OX40 values with Sample Diluent in order to precisely quantitate the actual human sCD134/OX40 level.**
- It is suggested that each testing facility establishes a control sample of known human sCD134/OX40 concentration and runs this additional control with each assay. If the values obtained are not within the expected range of the control, the assay results may be invalid.
- A representative standard curve is shown in Figure 8. This curve cannot be used to derive test results. Each laboratory must prepare a standard curve for each group of microwell strips assayed.

Figure 8
Representative standard curve for human sCD134/OX40 ELISA. Human sCD134/OX40 was diluted in serial 2-fold steps in Sample Diluent. Do not use this standard curve to derive test results. A standard curve must be run for each group of microwell strips assayed.



Table 2
Typical data using the human sCD134/OX40 ELISA
Measuring wavelength: 450 nm
Reference wavelength: 620 nm

Standard	Human sCD134/OX40 Concentration (pg/ml)	O.D. at 450 nm	Mean O.D. at 450 nm	C.V.(%)
1	5000	2.539 2.387	2.463	3.1
2	2500	1.559 1.598	1.579	1.2
3	1250	1.124 1.131	1.128	0.3
4	625	0.814 0.719	0.767	6.2
5	313	0.511 0.437	0.474	7.8
6	156	0.292 0.291	0.292	0.2
7	78	0.179 0.167	0.173	3.5
Blank	0	0.017 0.016	0.017	3.0

The OD values of the standard curve may vary according to the conditions of assay performance (e.g. operator, pipetting technique, washing technique or temperature effects). Furthermore shelf life of the kit may affect enzymatic activity and thus colour intensity. Values measured are still valid.

12. LIMITATIONS

- Since exact conditions may vary from assay to assay, a standard curve must be established for every run.
- Bacterial or fungal contamination of either screen samples or reagents or cross-contamination between reagents may cause erroneous results.
- Disposable pipette tips, flasks or glassware are preferred, reusable glassware must be washed and thoroughly rinsed of all detergents before use.
- Improper or insufficient washing at any stage of the procedure will result in either false positive or false negative results. Empty wells completely before dispensing fresh wash solution, fill with Wash Buffer as indicated for each wash cycle and do not allow wells to sit uncovered or dry for extended periods.
- The use of radioimmunotherapy has significantly increased the number of patients with human anti-mouse IgG antibodies (HAMA). HAMA may interfere with assays utilizing murine monoclonal antibodies leading to both false positive and false negative results. Serum samples containing antibodies to murine immunoglobulins can still be analysed in such assays when murine immunoglobulins (serum, ascitic fluid, or monoclonal antibodies of irrelevant specificity) are added to the sample.

13. PERFORMANCE CHARACTERISTICS

13.1 Sensitivity

The limit of detection of human sCD134/OX40 defined as the analyte concentration resulting in an absorbance significantly higher than that of the dilution medium (mean plus 2 standard deviations) was determined to be 1.8 pg/ml (mean of 6 independent assays).

13.2 Reproducibility

13.2.1 Intra-assay

Reproducibility within the assay was evaluated in 3 independent experiments. Each assay was carried out with 6 replicates of 8 serum samples containing different concentrations of human sCD134/OX40. 2 standard curves were run on each plate. Data below show the mean human sCD134/OX40 concentration and the coefficient of variation for each sample (see Table 3). The calculated overall intra-assay coefficient of variation was 8.0%.

Table 3
The mean human sCD134/OX40 concentration and the coefficient of variation for each sample

Sample	Experiment	Mean Human sCD134/OX40 Concentration (pg/ml)	Coefficient of Variation (%)
1	1	9281	5
	2	10139	8
	3	9966	11
2	1	5263	9
	2	4464	7
	3	3697	4
3	1	6570	13
	2	4659	6
	3	5658	8
4	1	3837	10
	2	2801	10
	3	3068	9
5	1	2503	3
	2	2230	6
	3	2495	7
6	1	8573	7
	2	6229	8
	3	6743	10
7	1	4809	9
	2	4223	5
	3	4070	6
8	1	1845	8
	2	1585	12
	3	1782	11

13.2.2 Inter-assay

Assay to assay reproducibility within one laboratory was evaluated in 3 independent experiments. Each assay was carried out with 6 replicates of 8 serum samples containing different concentrations of human sCD134/OX40. 2 standard curves were run on each plate. Data below show the mean human sCD134/OX40 concentration and the coefficient of variation calculated on 18 determinations of each sample (see Table 4). The calculated overall inter-assay coefficient of variation was 12.0%.

Table 4
The mean human sCD134/OX40 concentration and the coefficient of variation of each sample

Sample	Mean Human sCD134/OX40 Concentration (pg/ml)	Coefficient of Variation (%)
1	9796	4.6
2	4475	17.5
3	5629	17.0
4	3236	16.6
5	2409	6.5
6	7182	17.2
7	4367	8.9
8	1738	7.8

13.3 Spiking Recovery
The spiking recovery was evaluated by spiking 4 levels of human sCD134/OX40 into serum. Recoveries were determined in 3 independent experiments with 4 replicates each.
The unspiked serum was used as blank in these experiments.
The overall mean recovery was 88%.

13.3 Dilution Linearity
Serum samples with different levels of human sCD134/OX40 were analysed at serial 2 fold dilutions with 4 replicates each. Table 5 shows detailed recovery data of 4 serum samples.

Table 5

Sample	Dilution	Expected Human sCD134/OX40 Concentration (pg/ml)	Observed Human sCD134/OX40 Concentration (pg/ml)	Recovery of Expected Human sCD134/OX40 Concentration (%)
1	1:2	--	31176	--
	1:4	15588	16171	104
	1:8	8085	8847	109
	1:16	4423	4538	103
2	1:2	--	26701	--
	1:4	13350	14230	107
	1:8	7115	8330	117
	1:16	4165	5157	124
3	1:2	--	16152	--
	1:4	8076	8158	101
	1:8	4079	4985	122
	1:16	2492	2168	87
4	1:2	--	13339	--
	1:4	6670	8325	125
	1:8	4162	4427	106
	1:16	2213	2280	103

13.4 Sample Stability

13.4.1 Freeze-Thaw Stability

Aliquots of serum samples (spiked or unspiked) were stored at -20°C and thawed 5 times, and the human sCD134/OX40 levels determined. There was no significant loss of human sCD134/OX40 immunoreactivity detected by freezing and thawing.

13.4.2 Storage Stability

Aliquots of serum samples (spiked or unspiked) were stored at -20°C, 2-8°C, room temperature (RT) and at 37°C, and the human sCD134/OX40 level determined after 24 h. There was no significant loss of human sCD134/OX40 immunoreactivity detected during storage under above conditions.

13.5 Specificity

The assay detects both natural and recombinant human sCD134/OX40.
The cross reactivity of circulating factors of the immune system was evaluated by spiking these proteins at physiologically relevant concentrations into a human sCD134/OX40 positive serum. There was no crossreactivity detected.

13.6 Expected Values

There were no detectable human sCD134/OX40 levels found.
Elevated human sCD134/OX40 levels depend on the type of immunological disorder.

14. REFERENCES

1) Aten J, Roos A, Claessen N, Schilder-Tol EF, Ten Berge IJ, Weening JJ. Strong and selective glomerular localization of CD134 ligand and TNF receptor-1 in proliferative lupus nephritis. J Am Soc Nephrol. 2000 Aug; 11 (8): 1426-38.
2) Bansal-Pakala P, Croft M. Breaking Immunological Tolerance through OX40 (CD134). Scientfic WorldJournal. 2001 Nov 6; 1 (11):
3) Bansal-Pakala P, Jember AG, Croft M. Signaling through OX40 (CD134) breaks peripheral T-cell tolerance. Nat Med. 2001 Aug; 7
4) Blazar BR, Sharpe AH, Chen AI, Panoskaltsis-Mortari A, Lees C, Akiba H, Yagita H, Killeen N, Taylor PA. Ligation of OX40 (CD134) regulates graft-versus-host disease (GVHD) and graft rejection in allogeneic bone marrow transplant recipients. Blood. 2003 May 1; 101 (9): 3741-8. Epub 2003 Jan 09.
5) Croft M. Costimulation of T cells by OX40, 4-1BB, and CD27.Cytokine Growth Factor Rev. 2003 Jun-Aug; 14 (3-4): 265-
6) Durkop H, Latza U, Himmelreich P, Stein H. Expression of the human OX40 (hOX40) antigen in normal and neoplastic tissues. Br J Haematol. 1995 Dec; 91 (4): 927-31.
7) Giacomelli R, Passacantando A, Perricone R, Parzanese I, Rascente M, Minisola G, Tonietti G. T lymphocytes in the synovial fluid of patients with active rheumatoid arthritis display CD134-

OX40 surface antigen. Clin Exp Rheumatol. 2001 May-Jun; 19 (3): Gniadecki R, Rossen K. Expression of T-cell activation marker CD134 (OX40) in lymphomatoid papulosis. Br J Dermatol. 2003 May; 148 (5): 885-91.
9) Gramaglia I, Jember A, Pippig SD, Weinberg AD, Killeen N, Croft M. The OX40 costimulatory receptor determines the development of CD4 memory by regulating primary clonal expansion. J Immunol. 2000 Sep 15; 165 (6): 3043-50.
10) Hoshino A, Tanaka Y, Akiba H, Asakura Y, Mita Y, Sakurai T, Takaoka A, Nakaike S, Ishii N, Sugamura K, Yagita H, Okumura K. Critical role for OX40 ligand in the development of pathogenic Th2 cells in a murine model of asthma. Eur J Immunol. 2003 Apr ; 33 (4) : 861-9.
11) Humphreys IR, Walzl G, Edwards L, Rae A, Hill S, Hussell T. A critical role for OX40 in T cell-mediated immunopathology during lung viral infection. J Exp Med. 2003 Oct 20; 198 (8): 1237-42.
12) Imura A, Hori T, Imada K, Ishikawa T, Tanaka Y, Maeda M, Imamura S, Uchiyama T. The human OX40/gp34 system directly mediates adhesion of activated T cells to vascular endothelial cells. J Exp Med. 1996 May 1; 183 (5): 2185-95.
13) Ishii N, Ndhlovu LC, Murata K, Sato T, Kamanaka M, Sugamura K. OX40 (CD134) and OX40 ligand interaction plays an adjuvant role during in vivo Th2 responses. Eur J Immunol. 2003 Sep ; 33 (9) :
14) Jones D, Fletcher CD, Pulford K, Shahsafaei A, Dorfman DM. The T-cell activation markers CD30 and OX40/CD134 are expressed in nonoverlapping subsets of peripheral T-cell lymphoma. Blood. 1999 May 15; 93 (10): 3487-93.
15) Kotani A, Ishikawa T, Matsumura Y, Ichinohe T, Ohno H, Hori T, Uchiyama T. Correlation of peripheral blood OX40+ (CD134+) T cells with chronic graft-versus-host disease in patients who underwent allogeneic hematopoietic stem cell transplantation.Bloo 2001 Nov 15; 98 (10): 3162-4.
16) Kunitomi A, Hori T, Maeda M, Uchiyama T. OX40 signaling renders adult T-cell leukaemia cells resistant to Fas-induced apoptosis.Int J Hematol. 2002 Oct; 76 (3): 260-6.
17) Murata K, Nose M, Ndhlovu LC, Sato T, Sugamura K, Ishii N. Constitutive OX40/OX40 ligand interaction induces autoimmune-like diseases. J Immunol. 2002 Oct 15; 169 (8): 4628-36.
18) Ndhlovu LC, Ishii N, Murata K, Sato T, Sugamura K. Critical involvement of OX40 ligand signals in the T cell priming events during experimental autoimmune encephalomyelitis. J Immunol. 2001 Sep 1; 167 (5): 2991-9.
19) Rogers PR, Song J, Gramaglia I, Killeen N, Croft M. OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T cells. Immunity. 2001 Sep; 15 (3): 445-55.
20) Roos A, Schilder-Tol EJ, Weening JJ, Aten J. Strong expression of CD134 (OX40), a member of the TNF receptor family, in a T helper 2-type cytokine environment. J Leukoc Biol. 1998 Oct; 64 (4): 503-
21) Salek-Ardakani S, Song J, Halteman BS, Jember AG, Akiba H, Yagi H, Croft M. OX40 (CD134) controls memory T helper 2 cells that drive lung inflammation. J Exp Med. 2003 Jul 21; 198 (2): 315-24. Epub 2003 Jul 14.

22) Sato T, Ishii N, Murata K, Kikuchi K, Nakagawa S, Ndhlovu LC, Sugamura K. Consequences of OX40-OX40 ligand interactions in langerhans cell function: enhanced contact hypersensitivity responses in OX40L-transgenic mice. Eur J Immunol. 2002 Nov; 32 (11) : 3326-35.
23) Seko Y, Ishiyama S, Nishikawa T, Kasajima T, Hiroe M, Suzuki S, Ishiwata S, Kawai S, Tanaka Y, Azuma M, Kobata T, Yagita H, Okumura K, Nagai R. Expression of tumor necrosis factor ligand superfamily costimulatory molecules CD27L, CD30L, OX40L and 4- 1BBL in the heart of patients with acute moycarditis and dilated cardiomyopathy. Cardiovasc Pathol. 2002 May-Jun; 11 (3): 166-70.
24) Takahashi Y, Tanaka Y, Yamashita A, Koyanagi Y, Nakamura M, Yamamoto N. OX40 stimulation by gp34/OX40 ligand enhances productive human immunodeficiency virus type 1 infection. J Virol. 2001 Aug; 75 (15): 6748-57.
25) Takasawa N, Ishii N, Higashimura N, Murata K, Tanaka Y, Nakamura M, Sasaki T, Sugamura K. Expression of gp34 (OX40 ligand) and OX40 on human T cell clones. Jpn J Cancer Res. 2001 Apr; 92 (4): 377-82.
26) Taraban VY, Rowley TF, O'Brien L, Chan HT, Haswell LE, Green M, Tutt AL, Glennie MJ, Al-Shamkhani A. Expression and costimulatory effects of the TNF receptor superfamily members CD134 (OX40) and CD137 (4-1BB) and their role in the generation of anti-tumor immune responses. Eur J Immunol. 2002 Dec; 32 (12) :3617-27.
27) Tateyama M, Fujihara K, Ishii N, Sugamura K, Onodera Y, Itoyama Y. Expression of OX40 in muscles of polymositis and granulomatous myopathy. J Neurol Sci. 2002 Feb 15; 194 (1): 29- 34.
28) Taylor L, Schwarz H. Identification of a soluble OX40 isoform: development of a specific and quantative immunoassay. J Immunol Methods. 2001 Sep 1; 255 (1-2): 67-72.
29) Weinberg AD. OX40: targeted immunotherapy--implications for tempering autoimmunity and enhancing vaccines. Trends Immunol. 2002 Feb; 23 (2): 102-9.
30) Yoshioka T, Nakajima A, Akiba H, Ishiwata T, Asano G, Yoshino S, Yagita H, Okumura K. Contribution of OX40/OX40 ligand interaction to the pathogenesis of rheumatoid arthritis. Eur J Immunol. 2000 Oct; 30 (10): 2815-23.a

15. REAGENT PREPARATION SUMMARY

15.1 Wash Buffer (1x)

Add **Wash Buffer Concentrate** 20x (50 ml) to 950 ml distilled water.

Number of Strips	Wash Buffer Concentrate (ml)	Distilled Water (ml)
1 - 6	25	475
1 - 12	50	950

15.2 Assay Buffer (1x)

Add **Assay Buffer Concentrate** 20x (5 ml) to 95 ml distilled water.

Number of Strips	Assay Buffer Concentrate (ml)	Distilled Water (ml)
1 – 6	2.5	47.5
1 – 12	5.0	95.0

15.3 Biotin-Conjugate

Make a 1:100 dilution of **Biotin-Conjugate** in Assay Buffer (1x):

Number of Strips	Biotin-Conjugate (ml)	Assay Buffer (1x) (ml)
1 - 6	0.03	2.97
1 - 12	0.06	5.94

14.5 Streptavidin-HRP

Make a 1:100 dilution of **Streptavidin-HRP** in Assay Buffer (1x):

Number of Strips	Streptavidin-HRP (ml)	Assay Buffer (1x) (ml)
1 - 6	0.06	5.94
1 - 12	0.12	11.88

15.5 Human sCD134/OX40 Standard

Reconstitute lyophilized **human sCD134/OX40 standard** with distilled water. (Reconstitution volume is stated in the Certificate of Analysis.)

16. TEST PROTOCOL SUMMARY

1. Determine the number of microwell strips required.
2. Wash microwell strips twice with Wash Buffer.
3. Standard dilution on the microwell plate: Add 100 µl Sample Diluent, in duplicate, to all standard wells. Pipette 100 µl prepared standard into the first wells and create standard dilutions by transferring 100 µl from well to well. Discard 100 µl from the last wells. Alternatively external standard dilution in tubes (see 0): Pipette 100 µl of these standard dilutions in the microwell strips.
4. Add 100 µl Sample Diluent, in duplicate, to the blank wells.
5. Add 75 µl Sample Diluent to sample wells.
6. Add 25 µl sample in duplicate, to designated sample wells.
7. Prepare Biotin-Conjugate.
8. Add 50 µl Biotin-Conjugate to all wells.
9. Cover microwell strips and incubate 2 hours at room temperature (18° to 25°C).
10. Prepare Streptavidin-HRP.
11. Empty and wash microwell strips 3 times with Wash Buffer.
12. Add 100 µl diluted Streptavidin-HRP to all wells.
13. Cover microwell strips and incubate 1 hour at room temperature (18° to 25°C).
14. Empty and wash microwell strips 3 times with Wash Buffer.
15. Add 100 µl of TMB Substrate Solution to all wells.
16. Incubate the microwell strips for about 10 minutes at room temperature (18° to 25°C).
17. Add 100 µl Stop Solution to all wells.
18. Blank microwell reader and measure colour intensity at 450 nm.

Note: If instructions in this protocol have been followed samples have been diluted 1:4 (25 µl sample + 75 µl Sample Diluent), the concentration read from the standard curve must be multiplied by the dilution factor (x 4).



BioVendor – Laboratorní medicína, a.s.
Karasek 1767/1, 621 00 Brno, Czech Republic
Phone: +420-549-124-185, Fax: +420-549-211-460
E-mail: info@biovendor.com, sales@biovendor.com
Web: www.biovendor.com

There are BioVendor branches and distributors near you.
To find the office closest to you, visit **www.biovendor.com/contact**

BioVendor
Research
and Diagnostic Products